Table 5.
Clinical characteristics*
|
Total
n= 538 |
|
|---|---|
| Vascular factors | |
| Vascular Conditions | |
| Stroke, n (%) | 112 (21%) |
| Myocardial infarction, n (%) | 133 (25%) |
| Claudication, n (%) | 140 (26%) |
| Vascular Risk Factors | |
| Diabetes, n (%) | 118 (22%) |
| Hypertension, n (%) | 370 (69%) |
| Smoking (ever), n (%) | 175 (33%) |
| Other Vascular Factors | |
| Systolic BP proximate to death, mean (SD) | 128 (21) |
| Diastolic BP proximate to death, mean (SD) | 81 (11) |
| Body mass index proximate to death, mean (SD) | 26.0 (5.1) |
| Medications | |
| Aspirin, n (%) | 388 (72%) |
| Amiodarone, n (%) | 111 (21%) |
| Digoxin, n (%) | 85 (16%) |
| Statin, n (%) | 214 (40%) |
| Anti-hypertensive, n (%) | 438 (81%) |
| Insulin, n (%) | 37 (7%) |
| Oral hypoglycemic, n (%) | 81 (15%) |
| Laboratory factors** | |
| Lipid profile | |
| Total cholesterol, mean (SD) | 187 (40) |
| LDL, mean (SD) | 104 (33) |
| HDL, mean (SD) | 54 (16) |
| Hemoglobin A1C, mean (SD) | 6.0 (0.6) |
*
Data are derived from all study evaluations (coded as present if identified at least once across the study), unless otherwise specified.
**
At time of first aPL measurement or first available data.